Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-K stay in one workspace.
PCSA
$1.43
-3.89%
PCSA
· Processa Pharmaceuticals, Inc.
$1.43
-0.06 (-3.89%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 14, 2026
The latest filing states the doubt was alleviated.
“Following our acquisition of Vidya and closing of the related $200 million gross private placement (from which we received net proceeds of $183.3 million) on July 30, 2026, we believe our cash and cash equivalents will be sufficient to satisfy our cash requirements over the next 12 months and beyond. This represents a material change from what we reported in our 2025 Form 10-K that disclosed substantial doubt of our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$5.14M
Shares
2.79M
Volume · Oct 6
18.59K
Avg daily vol (3M)
223.63K
All webcasts
Earnings call · FY2020 Q4
Processa Pharmaceuticals, Inc. (PCSA) Q4 2020 Earnings Call
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Net income · derived Q4
-$9.73M
Research materials
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
8-K earnings release
Filed Mar 25, 2021 · complete as-filed document
SEC periodic report
10-K report
Filed Apr 7, 2021 · complete as-filed document